The Mom1 (Modi®er of Min-1) region of distal chromosome 4 was identi®ed during a screen for polymorphic modi®ers of intestinal tumorigenesis in Apc Min/+ mice. Here, we demonstrate that the Mom1 AKR allele consists of two genetic components. These include the secretory phospholipase Pla2g2a, whose candidacy as a Mom1 resistance modi®er has now been tested with several transgenic lines. A second region, distal to Pla2g2a, has also been identi®ed using ®ne structure recombinants. Pla2g2a AKR transgenic mice demonstrate a modest resistance to tumorigenesis in the small intestine and a very robust resistance in the large intestine. Moreover, the tumor resistance in the colon of Pla2g2a AKR animals is dosage-dependent, a ®nding that is consistent with our observation that Pla2g2a is expressed in goblet cells. By contrast, mice carrying the distal Mom1 modi®er demonstrate a modest tumor resistance that is con®ned to the small intestine. Thus, the phenotypes of these two modi®er loci are complementary, both in their quantitative and regional eects. The additive eects and tight linkage of these modi®ers may have been necessary for the initial identi®cation of the Mom1 region. Oncogene (2000) 19, 3182 ± 3192.
Introduction

Apc
Min/+ mice carry a germline mutation in the adenomatous polyposis coli (Apc) gene (Su et al., 1992; Shoemaker et al., 1997; Gould and Dove, 1998) . These animals have proven to be valuable models for studying genes that quantitatively aect the development of human colon cancer (Moser et al., 1990; Shoemaker et al., 1997; Gould and Dove, 1998) . Similar germline mutations in the homologous human APC gene lead to familial adenomatous polyposis (Groden et al., 1991) . Studies of Min on dierent genetic backgrounds have led to the identi®cation of novel modi®er loci Dietrich et al., 1993; Gould et al., 1996b) , while combinations of Min with other mutant strains have helped to elucidate the role in tumorigenesis of previously identi®ed genes, such as Dnmt1 (Laird et al., 1995; Cormier and Dove, in press) and p53 (Halberg et al., 2000) . The search for the ®rst polymorphic Min modi®er locus was prompted by the observation that progeny of (AKR6B6) F1 crosses developed only 20% as many intestinal adenomas as B6-Min control animals, indicating that the AKR strain carried one or more dominant resistance modi®ers ). An (AKR6B6) F16B6-Min backcross was employed to map a locus, Modi®er of Min-1 (Mom1), to a 15-cM region on distal chromosome 4. The genotype at Mom1 explained about 50% of the reduction in tumor multiplicity observed in (AKR6B6) F1 mice (Dietrich et al., 1993) . A Mom1 congenic strain was bred in which a 35-cM region of AKR distal chromosome 4 carrying Mom1 was introduced onto the B6 genetic background (Gould et al., 1996a) . Mom1 congenic heterozygotes that carried Min (B6-Min Mom1 AKR/B6 ) developed only 50% as many intestinal adenomas as B6-Min control siblings, whereas Mom1 congenic homozygotes that carried Min (B6-Min Mom1 AKR/AKR ) developed only 25% as many tumors, demonstrating that this modi®er acts semi-dominantly (Gould et al., 1996a) . Mom1
AKR was further shown to reduce net tumor growth rate (Gould et al., 1996a) , and probably to act non-cell autonomously, although within the crypt cell lineage (Gould et al., 1996c) . MacPhee and colleagues (1995) proposed Pla2g2a, the calcium-dependent non-pancreatic secretory phospholipase (Dennis, 1994) , as a candidate gene for Mom1. Pla2g2a maps to a region of distal mouse chromosome 4 that shares conserved linkage with human chromosome 1p35-36 . This candidacy was supported by concordance between Pla2g2a genotype and Mom1 phenotype in nine inbred strains that had been crossed to B6-Min, and subsequently backcrossed to B6 (Gould et al., 1996b) . Pla2g2a was found to have a frameshift mutation in three strains (B6, 129, and BTBR) that have a Mom1 allele that confers sensitivity to tumorigenesis, while Pla2g2a is wildtype in six strains (AKR, BALB, SWR, DBA, MA, and CAST) that carry a Mom1 resistance allele (MacPhee et al., 1995; Kennedy et al., 1995; Gould et al., 1996b) . However, another interesting candidate gene, Rap1Gap, also maps to the Mom1 region (Gould et al., 1996b) . Fine-structure recombinant mapping ultimately positioned Mom1 to a 4-cM interval that included Pla2g2a, but excluded Rap1Gap, on the basis of a single recombinant line (Gould et al., 1996b (Gould et al., 1996b) .
To test the hypothesis that Pla2g2a is responsible for part or all of the Mom1 phenotype, we analysed a transgenic line carrying the functional Pla2g2a AKR allele on a B6 background (Cormier et al., 1997) . Overexpression of Pla2g2a reduced intestinal adenoma multiplicity by 50%, similar to congenic B6-Min Mom1 AKR/B6 mice. However, the Pla2g2a AKR transgene did not add to the resistance phenotype of Mom1 AKR/B6 congenic mice. This observation was inconsistent with the known semi-dominant nature of Mom1's tumor resistance phenotype. This inconsistency may have resulted from unknown factors aecting the temporal and spatial regulation of transgene expression. Alternatively, the second component of Mom1, suggested by the studies of Gould et al. (1996b) , may have been lacking. To test the latter hypothesis and to extend our previous work, we have tested congenic recombinant lines that further separate the Mom1 interval into discrete regions whose recombinant breakpoints lie immediately distal to Pla2g2a. In addition, we have generated two more Pla2g2a , and examined the phenotypes of a larger set of test animals from the original transgenic line (Pla2g2a KH1 ).
Results
Recombinant lines divide the Mom1 region near D4Mit64 into two complementary resistance loci
Previous phenotyping of ®ne-structure recombinants in the Mom1 region revealed that B6-Min mice carrying the AKR allele of Pla2g2a are resistant to intestinal tumorigenesis (Gould et al., 1996b) . Notably, B6-Mom1 AKR -derived recombinant line 25 and its derivative line 32, which carry a Pla2g2a AKR allele, were only partially resistant when compared with the phenotype of heterozygous B6-Min Mom1 AKR congenic mice. To determine whether an AKR allele of a locus distal to Pla2g2a (which we ®nd to be recombinationally inseparable from D4Mit170) might confer the remainder of the Mom1 resistance phenotype, we tested the phenotype of recombinant line 57, whose breakpoint lies immediately distal to Pla2g2a, in the interval between D4Mit170 and D4Mit64. The AKR fragment carried in line 57 extends through the marker D4Mit180, potentially as far as the telomere at about 84-cM. Concurrently, we tested the phenotypes of lines 29 and 63, which, like recombinant line 25, carry a proximal Mom1 AKR segment that includes an AKRderived Pla2g2a (Figure 1) .
Heterozygous female recombinant mice were crossed to B6-Min males, and tumors were counted and measured along the intestinal tract of all Min progeny. Mice from recombinant line 29 developed signi®cantly fewer tumors than B6-Min control siblings (P=0.001), but they also developed signi®cantly more tumors than an age-matched class of B6-Min Mom1 AKR/B6 congenic mice (P50.05). Thus, recombinant line 29 demonstrated an intermediate tumor resistance phenotype. Recombinant line 63, which carries a smaller proximal AKR region than line 29 (Figure 1 ), also displayed a phenotype that was signi®cantly dierent from that of B6-Min control mice and that was marginally dierent (approaching statistical signi®-cance at P=0.08) from Mom1 AKR congenics. These data indicate that the region of AKR carried by lines 29 and 63 confers partial Mom1 resistance to intestinal tumorigenesis.
Min animals carrying the line 57 recombinant chromosome also display partial Mom1 resistance (see Figure 1 ). Line 57 mice develop signi®cantly fewer tumors than B6-Min siblings (P=0.01), but develop signi®cantly more than Mom1 AKR/B6 congenics (P=0.004). Thus, the proximal and distal AKR resistance alleles appear to be complementary, together approximating the resistance conferred by the entire AKR region present in an age-matched class of Mom1 AKR/B6 congenics. For example, the 40% reduction in intestinal tumor multiplicity observed in recombinant line 29 and the 25% reduction imparted by recombinant line 57, together approximate the 55 ± 60% reduction in tumor multiplicity seen, both currently and historically, in congenic mice heterozygous for the Mom1 AKR resistance allele. AKR recombinant lines (29, 63, and 57) , that divide the Mom1 locus near the marker D4Mit64. Following crosses to B6-Min mice, Min progeny from these lines were sacri®ced at about 94 days, and their overall and regional tumor multiplicities were determined. Lines 57, 63, and 29 were signi®cantly dierent than B6-Min control siblings and Mom1 congenics in tumor multiplicity (P50.05). Congenic line represents Mom1 AKR/B6 agematched class. Pla2g2a maps to *68 cM. AKR=&, B6=& Strikingly, the proximal and distal AKR resistance alleles dier with respect to their eects on dierent regions of the intestine. Tumor counts taken from 4-cm sections from the small intestine (proximal, medial, and distal) and from the entire colon revealed that recombinant lines 63 and 29 (like Mom1 AKR congenics) reduce tumorigenesis throughout the intestinal tract (Figure 1 ). By contrast, the eect of recombinant line 57 was observed only in the medial 4-cm region. This medial region lies adjacent to a tumor cluster region that extends towards the distal area of the small intestine (K Haigis, unpublished results). Thus, it is likely that line 57 aects not only the medial 4-cm region tested, but the tumor cluster region as well.
The partial resistance observed is seen in tumor size as well as number: recombinant lines 29, 57, (see Table  1 ) and 63 (data not shown), like Mom1 AKR congenics, showed a reduction in the average maximum diameter of adenomas measured in the small intestine at 90 days of age. This eect was stronger in the proximal than in the distal recombinant lines.
Tumor resistance phenotypes of Pla2g2a
AKR transgenic mice are similar to recombinant lines 63 and 29
We have studied the intestinal tumor phenotypes of three transgenic lines that carry a 41-kb DNA fragment from AKR that encodes a functional copy of the Pla2g2a gene (Cormier et al., 1997) . MinPla2g2a AKR transgenic lines reduce tumor multiplicity (Table 2) to an extent similar to recombinant lines 63 and 29 (see Figure 1) , which carry an AKR-derived copy of Pla2g2a. , the strongest Pla2g2a expressor in the large intestine, reduces colon tumor incidence by a factor greater than 10 (see Figures 2, 3 and Table 2 ).
The Pla2g2a AKR transgenics each confer a reduction in the size of tumors in the small intestine of mice as measured at 90 days of age (see Table 1 ). Pla2g2a AKR transgenics also appear to reduce the size of colonic adenomas, with the strongest eect in line 948 (data not shown). Transgenic line Pla2g2a KH1 , like Mom1 AKR (Gould et al., 1996a) , also slows the net growth rate of tumors in the small intestine, especially in the period between 90 and 120 days (data not shown). We note that, among these dierent mouse lines, Mom1 AKR congenics have the strongest eect on tumor growth rate (R Cormier, unpublished results), consistent with the hypothesis that Mom1 has more than one component. AKR also appears to reduce adenoma size in the large intestine in a dose-dependent fashion, but owing to the diculty of accurately measuring the diameters of the pedunculated colonic tumors, we have excluded these from our analysis. One-sided P values represent comparison of each group with age-matched B6-Min controls, often siblings. Studies utilizing recombinant lines 29, and 57 and Mom1 AKR congenics were scored by one observer (AJ Lillich), while analyses of Pla2g2a AKR transgenic lines KH1, 948 and 959 were scored by a dierent observer (RT Cormier), in a separate experiment. n=number of mice Pla2g2a AKR transgenic lines show strong tumor resistance in the large intestine and an intermediate but signi®cant eect in the small intestine. Following crosses to B6-Min, Min transgenic progeny were sacri®ced at 90 days of age, and tumors were counted from the entire intestinal tract. All three transgenic lines were signi®cantly dierent from B6-Min non-transgenic littermates (P50.05). n=number of mice Transgenic line Pla2g2a KH1 shows tumor resistance throughout the intestinal tract. Min transgenic mice were sacri®ced at 90 days of age, and their tumor multiplicities were counted from 4-cm regions from the proximal, medial, and distal small intestine
Pla2g2a is expressed by the goblet cells in the large intestine
We have determined that goblet cells are the source of Pla2g2a produced in the large intestine, while Pla2g2a is expressed by both goblet and Paneth cells in the small intestinal crypt (see Figures 3 and 4) . In the large intestine, immunostaining for Pla2g2a is detected only in the interior of the crypts, generally staining the mucinous, goblet-cell region facing the crypt lumen. The strong over-expression of Pla2g2a in goblet cells of line Pla2g2a 948 is illustrated in Figure 3a ,b. Consistent with Western blot analysis (Figure 2 ) weaker immunostaining in the large intestine was detected in transgenic lines Pla2g2a 959 ( Figure 3c ) and Pla2g2a
KH1
( Figure 3d ). B6 large intestine, mutant for Pla2g2a, is shown in Figure 3e ,f. Interestingly, while we cannot detect Pla2g2a signal in Western blots (Figure 2 ), we have consistently observed a very faint immunostaining for Pla2g2a (above the minus-antibody control), which may be recognizing other type II-Pla2s (such as Pla2g2d) which are expressed at low levels in the mouse intestine. The goblet cell-speci®c spatial expression pattern of Pla2g2a was con®rmed in serial sections obtained from transgenic line Pla2g2a 948 that were stained for alcian blue, which detects the acidic mucopolysaccharides of goblet cells (Figure 4) . Enterocytes of the intercrypt table facing the main intestinal lumen do not stain positively for either Pla2g2a or alcian blue (Figure 4c,d ). In the large intestine, goblet cell expression by Pla2g2a is very apparent by direct comparison of serial sections stained for either alcian blue or Pla2g2a Ab (Figure 4a ± d) . There is nearly complete concordance in alcian blue and Pla2g2a staining pro®les. We can also detect Pla2g2a immunostaining and alcian blue staining in the small intestine (Figure 4e,f) .
The ®nding that Pla2g2a is expressed by the goblet cell population may shed light on the phenotypes seen in Pla2g2a
AKR transgenic lines and in proximal region recombinant lines. Goblet cells represent only *5 ± 10% of epithelial cells in the small intestine but more than 60% in the large intestine (Paulus et al., 1993; Itoh et al., 1999) . The Pla2g2a transgene confers only a modest tumor resistance in the small intestine, but a far more robust response in the large intestine. These regional dierences may be attributable to the relative distribution of goblet cells in the dierent regions of the intestine.
Pla2g2a
AKR transgenic mice develop normally Pla2g2a AKR mice appear phenotypically identical to non-transgenic littermates. Pla2g2a transgenic mice do not develop any of the abnormalities reported in mice expressing a human PLA2G2A transgene (Grass et al., 1996; Nevalainen et al., 1997) , such as epidermal and adnexal hyperplasia, hyperkeratosis, alopecia, and juvenile cachexia. This ®nding may not be surprising since mPla2g2a and hPLA2G2A may dier in some physiological functions, as suggested recently by Lambeau and colleagues (Cupillard et al., 1999) . These dierences may extend to intestinal functions and therefore account for some of the diculty in reconciling mPla2g2a's tumor resistance with some of the known actions of hPLA2G2A (discussed further below).
The intestine of transgenic mice also appears identical to non-transgenic siblings, with no observed dierences in tissue architecture, length, or intestinal crypt height. Transgenic line Pla2g2a KH1 does appear to have an increased frequency of microphthalmia and anophthalmia (R Cormier and K Hong, unpublished observations), but this phenotype was not observed in lines Pla2g2a
or Pla2g2a
959
, which express the transgene at equivalent or higher levels in the intestine. This suggests that the Pla2g2a KH1 eye phenotype may be speci®c to either its genomic insertion site or its regulation in cells of the eye lineage.
Discussion
Mom1 is a complex locus
Our functional studies of the Mom1 region illustrate some of the challenges inherent in the identi®cation of quantitative trait loci (QTLs). While the use of inbred mice permits the generation of large mapping populations, current methodologies provide only limited resolution, even with the increasing availability of genetic markers. One is still left with the task of sifting through a fairly large and diverse set of candidate genes even in a relatively small region such as the Mom1 locus (discussed by Dragani and Manenti, 1997 ). This diculty is compounded when the QTL consists of multiple polymorphic modi®ers, as we have shown here for Mom1. Ultimately, suitable candidates require functional genetic tests such as targeted knockouts, knockins, or the addition of transgenic DNA fragments.
We have generated three transgenic lines to test the function of Pla2g2a AKR , expressed on a B6 background. (lanes 5 ± 6), (20 mg) and a B6 control (lanes 7 ± 8), (40 mg). These extracts were subjected to Western blot analysis with Pla2g2a antiserum. Pla2g2a
KH1
is a positive control for Pla2g2a immunoreactivity (Cormier et al., 1997) ; B6 mice are a negative control, since they are naturally mutant for Pla2g2a. Note that the lanes 1 ± 6 were exposed for 15 s while lanes 7 ± 8 were exposed for 5 min. Signals were quantitated and normalized to Mom1 AKR/AKR (band not shown The phenotypes of these three lines provide clear genetic evidence that Pla2g2a provides active resistance to intestinal tumorigenesis in the mouse and accounts for a part of the Mom1 phenotype. This resistance is robust in the large intestine, with Pla2g2a appearing to provide all of the Mom1 eect in the colon. For example, transgenic line Pla2g2a 948 reduced colon tumor multiplicity by a factor greater than 10. However, in the small intestine, Pla2g2a expression consistently provides only a modest reduction in tumor multiplicity (*30%). The phenotypes of proximal AKR region recombinant lines 29 and 63 resemble the phenotypes of the transgenic lines in having a broad intestinal tissue speci®city and in displaying a resistance that is quantitatively intermediate between that of the B6-Min and B6-Min Mom1 AKR/B6 classes. This analysis is also consistent with the phenotypes of recombinant lines 25 and 32, reported by Gould et al. (1996b) to display intermediate resistance. Lines 25, 32, and 29 all carry an AKR region from chromosome 4 de®ned by the markers D4Mit12 to D4Mit64. We note that a previous analysis of recombinant line 29 did not reveal a statistically signi®cant intermediate phenotype (Gould et al., 1996b) . In that study, line 29 developed a number of tumors in the standard four intestinal regions sampled that was statistically indis- Analysis of a ®ne-structure recombinant (line 57), whose breakpoint lies immediately distal to D4Mit170, indicates that the complementary partner, or partners, for Pla2g2a in the small intestine lie in this distal Mom1 region, probably mapping distal of D4Mit64. Our data suggest that this distal recombinant line provides tumor resistance that is restricted to a de®ned region of the small intestine, in an area that is likely to extend from the medial section into the adjacent tumor cluster site. This restriction observed in line 57's eect is unlike the broad range of action observed in the proximal recombinant lines, Pla2g2a AKR transgenic lines, or Mom1 Line 52, which carries an AKR fragment whose breakpoint lies distal of D4Mit64, supports the identi®cation of a second Mom1 component and suggests that it lies at least 2-cM from Pla2g2a. This line resembles line 57 in conferring a modest resistance that is con®ned to the medial region of the small intestine (data not shown). This eect is only suggestive, however, (P=0.095). Considered together, the data from lines 57 and 52 and the fact that proximal line 29's breakpoint is also distal to D4Mit64 suggest that the distal Mom1 modi®er lies between D4Mit64 and the telomere.
Parenthetically, we note that the phenotype of Pla2g2a KH1 transgenic mice varies from that previously reported by our group (Cormier et al., 1997) . Tumor multiplicities from a much larger set of 69 transgenic mice demonstrated only a 28% reduction in overall tumor number, which is signi®cantly dierent from our previous report of a 50% reduction in tumors, scored from an initial set of 10 transgenic mice. One potential explanation for this variance is a`litter eect' that we have observed in Min tumor phenotypes. Severe or attenuated tumor phenotypes often cluster within litters, a ®nding that may necessitate larger sample sizes. Notably, the 28% reduction in tumors observed in the larger set of KH1 transgenic mice is similar to the phenotypes of lines 948 (734%) and line 959 (724%).
Pla2g2a, lipid metabolism, and intestinal cancer
The nomination of Pla2g2a as a negative regulator of tumorigenesis in the intestine has been controversial. With a single exception (Nimmrich et al., 1997) , loss of Pla2g2a has not been observed in human colon cancer (Riggins et al., 1995; Praml et al., 1998; Dobbie et al., 1997; Spirio et al., 1996) , although as noted by Dove et al. (1994) , Gould et al. (1996a), and MacPhee et al. (1995) , one would not expect to observe LOH for a secreted factor that presumably acts non-cell autonomously within the mouse intestinal crypt.
One function of Pla2g2a is to catalyze the enzymatic release of long-chain fatty acids, such as arachidonic acid, at the sn-2 position of membrane glycerophospholipids. Arachidonic acid is a substrate for cyclooxygenases 1 and 2 (COX-1 and COX-2), the primary enzymes responsible for prostaglandin biosynthesis (Herschmann, 1996; Murakami et al., 1998 Murakami et al., , 1999 Vane et al., 1998; Fourcade et al., 1995; Balsinde et al., 1998; Tisch®eld, 1997) . COX-2 has been implicated genetically (Oshima et al., 1996) and pharmacologically (Yang et al., 1998; Shi et al., 1995; Piazza et al., 1995; Tsujii and Dubois, 1995; Tsujii et al., 1997; BeazerBarclay et al., 1996; Mahmoud et al., 1998; Boolbol et al., 1996; Jacoby et al., 1996; Taketo, 1998; Rao et al., 1995; Quesada et al., 1998; Nakatsugi et al., 1997) in the enhancement of intestinal tumorigenesis in both humans and rodents. Further, COX-2 is reported to be upregulated in both human colon cancer and in Min adenomas (Williams et al., 1996) . The designation of COX-2 as a positive tumor regulator has led to the proposal that other genes (such as PLA2G2A) and various eicosanoids in the COX-2 pathway might also positively impact the adenoma and thus should be considered appropriate therapeutic targets (Ikegami et al., 1998; Rao et al., 1996) . However, accumulating data suggest that Pla2G2a and the prostaglandin biosynthetic pathway are not associated with COXdependent tumorigenesis. Non-steroidal anti-in¯amma-tory drugs (NSAIDs) that target COX-2 have been shown to induce regression of Min adenomas independent of prostaglandin biosynthesis (Chiu et al., 1997; Moorghen et al., 1998; Mahmoud et al., 1998) . NSAIDs can also inhibit the proliferation of human colon cancer cells (Hanif et al., 1996; Erickson et al., 1999; McCracken et al., 1996; Levy, 1997) , as well as chemically induced colon tumors in rats (Reddy et al., 1999; Charalambous et al., 1998) , independent of prostaglandins. Crucially, the molecular genetic studies reported in this paper and its predecessors provide strong evidence that Pla2g2a diminishes, rather than enhances, intestinal tumorigenesis in the mouse, particularly in the large intestine, where this eect is dosage-dependent.
Pla2g2a: a role in mucosal barrier function?
Immunohistochemical analysis of Pla2g2a in the large intestine of transgenic mice shows that Pla2g2a is robustly expressed by the goblet cells (Figures 3 and 4) . In the small intestine Pla2g2a is predominantly expressed by the Paneth cells that reside at the base of the crypt of Lieberkuhn (Ouellette, 1997; Mulherkar et al., 1993; Cormier et al., 1997) . In this study we also detected Pla2g2a immunostaining in random goblet cells in the small intestine (Figure 4f ). These observations are consistent with the hypothesis of Garabedian et al. (1997) that goblet and Paneth cells share a common precursor in the small intestine. These investigators found that residual Pla2g2a expression continued to be detected in the mouse small intestine after Paneth cell ablation.
In the large intestine, products of the goblet cells are thought to protect the mucosa from injury, possibly by preventing bacterial invasion that would prompt damaging host immune responses (Fukushima et al., 1999) . Pla2g2a expression in the goblet cell population could help to maintain mucosal homeostasis (and thus resist tumorigenesis) by management of bacterial populations, either through its potent bactericidal functions (Mulherkar et al., 1991; Harwig et al., 1995; Weinrauch et al., 1998; Qu and Lehrer, 1998; Laine et al., 1999) or via the production of lipid signaling mediators, such as arachidonic acid and prostaglandins. A distinct function of prostaglandins in the intestine is to protect against mucosal injury, such as that caused by in¯ammatory bowel disease (IBD), and promote wound healing (Newberry et al., 1999; Cohn et al., 1997; Elder et al., 1997) . One histopathological characteristic of IBD in mice and humans (and also frequently observed in Min adenomas, R Cormier, unpublished) is the depletion of the goblet cell population (Fukushima et al., 1999) . Potential interactions between functions of Pla2g2a (prostaglandin biosynthesis, bactericidal), susceptibility to IBD, and colon tumorigenesis warrant further investigation with appropriate mouse models.
Regional modifiers of neoplasia
In our current study we have rearmed the role of Pla2g2a in providing intestinal tumor resistance in the mouse, and we have mapped a second component of Mom1 that lies distal to Pla2g2a and D4Mit64. This second locus provides a more modest resistance eect that is restricted to a de®ned region of the small intestine. Recent studies by our group and others indicate that the mouse intestine consists of discrete subregions that are dierentially susceptible to tumorigenesis. Other modi®ers of the Min phenotype act regionally within the intestine (A Bilger and WF Dove, unpublished results; Cormier and Dove, manuscript submitted), as do several Apc-independent tumor regulators such as TGFb-1 and Smad3, which develop neoplasia that is restricted to the large bowel (Engle et al., 1999; Zhu et al., 1998) . NSAIDs such as piroxicam have been reported to be relatively ineective in speci®c regions of the Min intestine, such as the duodenum and colon (Ritland and Gendler, 1999) . Thus, it is not surprising that the two components of Mom1 AKR exert dierential regional eects. In fact, it may turn out to be of greater novelty that Pla2g2a demonstrates its resistance phenotype throughout the intestine. One exception to this broad range of resistance, however, is the incidence of duodenal periampullar adenomas. This tumor type occurs in approximately 25% of Min mice, but none of several genetic modi®ers recently studied in our laboratory (Mom1, Pla2g2a AKR , or Dnmt1 N/+ ) have aected its development.
Distal Mom1 candidates
What is the identity of the second gene in the Mom1 region? Answering this question will require functional genetic tests such as those that have been performed here for Pla2g2a. As with Pla2g2a, this approach will initially require suitable test candidates. The Mom1 locus lies in a region of mouse distal chromosome 4 that is syntenic with human chromosome 1p35-36 Praml et al., 1995) , a region prone to LOH in a variety of human cancers, including familial and sporadic human colon cancer (Tomlinson et al., 1996; Herzog et al., 1995; MacPhee et al., 1995) . The list of candidates from the syntenic region of mouse distal chromosome 4 includes the recently expanding family of type IIsPla 2 that have been mapped to the same region of distal chromosome 4 Ishizaki et al., 1999; Murakami et al., 1999) . Examples are II-D and II-F, each expressed at low levels in the mouse intestine. We have excluded II-C and V as candidates for the distal resistance gene because we have found that polymorphisms in intron 3 of Pla2gV and in the 3' untranslated region of Pla2g2c segregate with the AKR region of recombinant line 25, which lacks the distal AKR resistance allele. In addition, we showed previously that Pla2gV lies only 8-kb from Pla2g2a (Cormier et al., 1997) . Another potential candidate in this region is Hspg2 (heparan sulfate proteoglycan 2), a basement membrane perlecan that has been mapped at 71.4 cM and is polymorphic among inbred strains AKR/J, C3H/HeJ, DBA/2J (Mom1 resistant and Pla2g2a + ) and C57BL/ 6J (Mom1 sensitive and Pla2g2a
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). Glypicans, also members of the heparan sulfate proteoglycan family, have been shown to bind and activate Pla2g2a (Murakami et al., 1999) .
Summary
While not all genetic factors identi®ed in the mouse may prove useful in the genetic epidemiology of the human, or even in treating human colon cancer, the use of inbred mouse strains should continue to identify candidate genes and biochemical pathways for further analysis and potential testing in clinical studies. The work reported here emphasizes both the feasibility of polymorphic modi®er identi®cation, such as for Pla2g2a, as well as its potential for complexity, as illustrated by our dissection of the Mom1 region into at least two tightly linked, additive modi®ers.
This ®nding of complexity is not unique. QTL analyses of disease phenotypes in mouse models (of lupus, diabetes, epilepsy and plasmacytoma) have recently identi®ed several clusters of tightly linked modi®ers whose individual eects were known only when the modi®er region was dissected by ®ne-structure mapping (Potter et al., 1994; Podolin et al., 1997 Podolin et al., , 1998 Legare et al., 2000; Morel et al., 1999) . It remains to be seen to what extent the ascertainment bias generated by modi®er clusters complicates the identi®cation of polymorphic modi®ers.
Materials and methods
Animal care and breeding
Experimental mice were bred at the McArdle Laboratory for Cancer Research. Mouse husbandry was performed as previously described (Cormier et al., 1997) .
Strain designations
Strains are designated throughout as B6 (C57BL/6J), B6-Min (B6-Apc Min/+ , or AKR (AKR/J).
Construction of transgenic lines
Cosmid KH1 was isolated and transgenic line Pla2g2a KH1 was generated and maintained as previously described (Cormier et al., 1997) . Transgenic lines Pla2g2a 948 and Pla2g2a 959 were generated by injecting a puri®ed 41-kb insert from cosmid KH1 into pronuclei of fertilized B6 mouse eggs. This procedure was conducted by the UW-Madison Biotechnology Center Transgenic Animal Facility. Transgenic mice were screened by PCR with DNA prepared from tail biopsies as described (Cormier et al., 1997) .
Experimental classes of mice
The B6-Min pedigree has been maintained by backcrossing B6-Apc Min/+ males to B6 females (n445). The B6-Mom1 AKR congenic strain has been maintained as previously described (Gould et al., 1996a) (n514) . Crosses involving Pla2g2a AKR transgenic line KH1 have been previously described (Cormier et al., 1997) . Females from Pla2g2a AKR transgenic lines 948 and 959 were crossed to B6-Min males to produce Min progeny carrying the transgene. Non-transgenic Min siblings were used as controls. Recombinant lines 29, 57, 63, and 52 were generated and have been maintained as previously described (Gould et al., 1996b ; n=10 ± 12 backcross generations). Females from recombinant lines 29, 52, 57, and 63 were crossed to B6-Min males. Min progeny carrying recombinant chromosomes were compared with Min sibling control animals that were homozygous for B6 alleles. All mice were sacri®ced at 90 days of age unless otherwise indicated. Age-matched Min Mom1 AKR/B6 congenic mice were also used for comparison in this analysis.
Intestinal tumor scoring and sizing
All mice were sacri®ced by CO 2 asphyxiation. The entire intestinal tract was removed, prepared, and ®xed as previously described (Cormier et al., 1997) . Tumors (50.4 mm for the Pla2g2a AKR transgenic experiments and 50.15 mm for the recombinant studies) were scored from ®xed tissues with a Nikon SMZ-U dissecting microscope at 106 (transgenic studies) or 206 (recombinant studies) magni®cation. Tumor sizes were estimated by measuring the maximum diameter of tumors from the small or large intestine with a calibrated eyepiece reticle. In each experiment, all tumors were counted and sized by a single observer who was blind to the genotype of the samples.
Genotyping
DNA was isolated from blood as described previously (Gould et al., 1996b) . The genotype of the Apc locus was determined by a PCR assay as described (Dietrich et al., 1992) . The Mom1 genotype was assigned on the basis of PCR analysis of the closely¯anking markers D4Mit54 and D4Mit13 (for the transgenic experiment) and D4Mit12, D4Mit13, and D4Mit180 (recombinant experiment) as described (Gould et al., 1996a) . The Pla2g2a transgenic genotype was determined by PCR using the primers T7 and Pla47b as previously described (Cormier et al., 1997) . In the recombinant experiments, Pla2g2a genotype was determined by PCR using the primers Pla2s8F and Pla2s144R (Gould et al., 1996a) . Mice carrying recombinant chromosomes (lines 29, 57, 63) were designated recombinant if they were heterozygous for¯anking markers as described (Gould et al., 1996b ; also describes chromosome 4 markers used in this analysis).
Western-blot analysis
The intestine was removed, opened, washed in phosphatebuered saline (PBS), divided into segments, and minced with a razor blade. The tissue was suspended in 1 M acetic acid and incubated overnight at 48C. Samples were centrifuged at 4000 r.p.m. in a swinging bucket rotor for 30 min, and the supernatant was transferred to a clean tube and stored at 7208C. Western blot analysis was performed as described (Halberg and Kroos, 1992) , except that 0.1 volume of 10 N NaOH was added to samples before electrophoresis and blots were probed with a 1 : 2000 dilution of rabbit polyclonal antiserum against Pla2g2a (Mulherkar et al., 1993) . Immunodetection with goat anti-rabbit horseradish peroxidase conjugate (Bio-Rad) and ECL Western blotting kit (Amersham) was performed according to the manufacturer's instructions. All signals were within the linear response range, as determined by a titration curve that was generated by loading increasing amounts of extract prepared from the small intestine of transgenic animals. Signals were quantitated with a Molecular Dynamics densitometer and software.
Immunohistochemistry
The Pla2g2a antiserum (Mulherkar et al., 1993) was used, at a 1 : 30 000 dilution, for standard peroxidase-based immunohistochemistry. The intestine was cut longitudinally, rinsed in 16PBS, washed, transferred to 70% ethanol, embedded in paran, and serially sectioned (5 mM). The sections were then dewaxed and rehydrated through a graded ethanol series. Antigen retrieval was performed by heating the slides in citrate buer (pH 6) for 25 min on full power in a 650-W Kenmore microwave oven. Endogenous peroxidase activity was quenched by incubation of the slides in 0.03% hydrogen peroxide solution for 15 min at room temperature. Immunohistochemistry was performed with the ABC elite peroxidase system (Vector) according to the manufacturer's instructions. Sections were developed in diaminobenzidine substrate (Sigma) and counterstained with hematoxylin for 5 s.
Alcian blue staining
To establish the identity of cells in the large intestine expressing Pla2g2a, adjacent serial sections were stained with alcian blue (8GX), pH 2.5. This stain detects the acidic mucopolysaccharides expressed by goblet cells. Sections were deparanized and rehydrated in distilled water, incubated in 3% acetic acid solution for 3 min, stained in alcian blue solution for 30 min, washed in running water for 10 min, rinsed in distilled water, counterstained in ®ltered nuclear fast red (Kernechtrot) solution for 5 min, washed in running water for 1 min, and dehydrated through an ethanol series.
Statistics
One-sided P values for intestinal tumor numbers and sizes were determined by comparison of each test class with contemporaneous B6-Min control mice (generated from the same cross) by use of the non-parametric Wilcoxon Rank Sum test. These tests were performed with the MStat statistical analysis software (N Drinkwater, UW-Madison, WI, USA). 
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